June 20th 2025
The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.
How treating food allergies and AD has changed
September 27th 2019Food allergies are a hot topic on the playground, at schools, and in pediatric offices. Parents of children with eczema or atopic dermatitis (AD) often have a lot of questions regarding the connection between eczema, exposure to common food allergens, and the development of or exacerbation of AD. There are many of the complex questions that clinicians must answer when evaluating pediatric patients with AD.